Seasonal affective disorders – includes information handout for patients
S. Atezaz Saeed
Depressive episodes are a primary public health problem and one of the most common psychiatric conditions in patients seeing family physicians, with a lifetime prevalence of 17.1 percent in the general population. Some of these mood disturbances follow regular seasonal patterns. These seasonal mood patterns have been termed seasonal affective disorders (SADs).
The Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) describes SAD not as a separate mood disorder but as a “specifier,” referring to the seasonal pattern of major depressive episodes that can occur within major depressive and bipolar disorders.
Table 1 summarizes the DSM-IV criteria for a major depressive episode. Table 2 describes the diagnostic criteria for “seasonal pattern specifier.”
Diagnostic Criteria for a Major Depressive Episode
A. At least five of the following symptoms have been present during
the same two-week period, nearly every day, and represent a
change from previous functioning. At least one of the symptoms
is either (1) depressed mood or (2) loss of interest or
NOTE: Do not include symptoms that are clearly due to a general
medical condition, or mood-incongruent delusions or
(1) Depressed mood (or alternatively can be irritable mood in
children and adolescents).
(2) Markedly diminished interest or pleasure in all, or almost
(3) Significant weight loss when not dieting or weight gain or
decrease or increase in appetite.
(4) Insomnia or hypersomnia.
(5) Psychomotor agitation or retardation.
(6) Fatigue or loss of energy
(7) Feelings of worthlessness or excessive or inappropriate
(8) Diminished ability to think or concentrate, or
(9) Recurrent thoughts of death (not just fear of dying),
recurrent suicidal ideation without a specific plan, or a
suicide attempt or a specific plan for committing suicide.
B. The symptoms are not better accounted for by a mood disorder due
to a general medical condition, a substance-induced mood
disorder, or bereavement (normal reaction to the death of a
C. The symptoms are not better accounted for by a psychotic
disorder like schizoaffective disorder.
Reprinted with permission from American Psychiatric Association.
Diagnostic and statistical manual of mental disorders. 4th ed.
Washington, D.C.: American Psychiatric Association, 1994:327.
Criteria for Seasonal Pattern Specifier
A. Regular temporal relationship between the onset of major
depressive episodes and a particular time of the year (unrelated
to obvious season-related psychosocial stressors)
B. Full remissions (or a change from depression to mania or
hypomania) also occur at a characteristic time of the year
C. Two major depressive episodes meeting criteria A and B in last
two years and no nonseasonal episodes in the same period
D. Seasonal major depressive episodes substantially outnumber the
nonseasonal episodes over the individual’s lifetime
Reprinted with permission from American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, D.C.: American Psychiatric Association, 1994:390. Copyright 1994.
Two seasonal patterns have been identified. The most often recognized is the fall-onset type, also known as “winter depression,” in which major depressive episodes begin in the late fall to early winter months and remit during the summer months. Atypical signs and symptoms of depression predominate in cases of winter depression and include the following: (1) increased rather than decreased sleep; (2) increased rather than decreased appetite and food intake with carbohydrate craving; (3) marked increase in weight; (4) irritability; (5) interpersonal difficulties (especially rejection sensitivity), and (6) leaden paralysis (a heavy, leaden feeling in the arms or legs).
A spring-onset pattern (summer depression) also has been described, in which the severe depressive episode begins in late spring to early summer and is characterized by typical vegetative symptoms of depression, such as decreased sleep, weight loss and poor appetite.
Recent studies report that most episodes of SAD occur within unipolar major depressive disorders, although a substantial minority have accompanying hypomanic episodes (bipolar II disorder, according to the DSM-IV), and very few are associated with manic episodes.
Surveys estimate that 4 to 6 percent of the general population experience winter depression, and another 10 to 20 percent have subsyndromal features. Women with SAD out-number men four to one. The average age of onset is approximately 23 years of age. The risk of SAD appears to decrease with age. Pilot studies of childhood cases of SAD suggest a prevalence rate between 1.7 and 5.5 percent in children between the ages of nine and 19 years.
Syndromal Validity and Utility
An understanding of the features and treatment of SAD has grown within the context of a debate about the validity of SAD as a syndrome. For example, it has been suggested that seasonal variations in mood and behavior noted in the general population speak against SAD as a distinctive diagnostic entity. In addition, symptoms of SADs overlap with other, more established subtypes of depression–summer depressions with typical depressive episodes and winter depression with atypical depression.[8,9] Winter depression responds to treatment with monoamine oxidase inhibitors (MAOIs), does atypical depression. Although summer depression has been studied less extensively than winter depression, it appears to respond to the same antidepressant pharmacotherapy that is used effectively to treat nonseasonal depression.
Some investigators have argued that the validity of SAD as a syndrome is supported by reports that the ratio of winter depression to summer depression increases with increasing latitude and that episodes of winter depression in particular tend to be longer and more severe at higher latitudes. In addition, although manipulation of factors such as heat and humidity has not been effective in treating summer depression, winter depression has responded to artificial bright light therapy, also known as phototherapy. Interestingly, nonseasonal atypical depression has not responded to phototherapy.
This issue is further complicated by the fact that although phototherapy has proved effective in the treatment of winter depression, its mechanism of action has not been established. Several mechanisms have been advanced, including circadian phase shifting, or reversing the increased melatonin, decreased 5-hydroxytryptamine and decreased dopamine neurotransmission observed in SAD, but it remains unestablished whether phototherapy achieves its well-documented effects through any of these or other mechanisms. Until further research clarifies these issues, phototherapy offers physicians an additional effective treatment option for clearly established cases of winter depression and justifies efforts made to identify this seasonal pattern in patients with depressive episodes.
Treatment Options and Guidelines
Although light therapy is uniquely effective for winter depressive episodes, treatment planning for patients with SAD should include consideration of all treatment options available, including somatic and psychosocial treatments.
The Agency for Health Care Policy and Research (AHCPR) has recently recommended practice guidelines for depression in primary care, including treatment of seasonal depression. According to these guidelines, the use of light therapy should be considered only in patients with well-documented seasonal, nonpsychotic, winter depressive episodes occurring within recurrent major depressive disorder, bipolar II disorder or milder seasonal depressive episodes. It is also advised that physicians unfamiliar with light therapy consult a professional who is experienced and trained in its use. Light therapy is a first-line treatment consideration under the circumstances listed in Table 3. It is also a second-line option in patients who fail to respond to an adequate trial of medication.
Circumstances Supporting the First-Line Use of Light Therapy
The patient is not severely suicidal.
There are medical reasons to avoid the use of antidepressants.
Patient has a history of favorable response to light therapy.
Patient has no history of significant negative effects to light
The patient requests light therapy.
An experienced practitioner deems that light therapy is indicated.
Information from reference 14.
Light therapy is initiated with a 10,000-lux light box directed toward the patient at a downward slant. The patient’s eyes should remain open throughout the treatment session, although staring directly into the light source is unnecessary and is not advised. The patient should start with a single 10- to 15-minute session per day, gradually increasing the session’s duration to 30 to 45 minutes. Sessions should be increased to twice a day if symptoms worsen. Ninety minutes a day is the conventional daily maximum duration of therapy, although there is no reason to limit the duration of sessions if side effects are not severe.
Commercially available fixtures are recommended over homemade devices to reduce electric risks associated with poor-quality construction. Commercial fixtures also include features designed to protect the eyes, such as light dispersion and screens that eliminate ultraviolet (UV) rays. Fluorescent light is preferred over incandescent because the small point source of the latter is more conducive to retinal damage. Use of “full-spectrum” light appears to be unnecessary.
No time of day is optimal for light therapy. Some studies have reported the superiority of morning sessions, while others have shown no significant difference between times of administration. In the absence of clear indications, convenience should be the prevailing consideration.
Although some patients show an immediate benefit from light therapy, most take two to four days to experience a sustained antide-pressant response. However, a lack of response within the first week should not be interpreted as a treatment failure, since evidence suggests that longer durations of therapy can improve response and that the initial response to light can take several weeks to appear. The treatment plan should be reevaluated, however, if the patient shows any clinical worsening or if a response is not evident in four to six weeks.
Patients who respond to light therapy should continue treatment until sufficient daily light exposure is available to them through other sources, typically from springtime sun. Premature discontinuation can precipitate relapse.
Recently, light visors have been manufactured that can deliver similar illumination in a more convenient and portable fashion. However, although studies using light boxes have suggested a positive relationship between the intensity of light and the clinical response, results from studies of light visors have not shown such a relationship. Some investigators have concluded that light boxes operate differently from visors.
It is important to note that no evidence indicates that tanning beds, where the eyes are generally covered and the subject’s skin is exposed to light, are useful in the treatment of SAD. Furthermore, the light sources in tanning beds are relatively high in UV rays, which can be harmful to both the eyes and the skin.
When properly administered, light therapy appears to have few side effects, none of which is irreversible. Caution is required when using light therapy in patients with a tendency toward mania, or in those with photosensitive skin or medical conditions that render their eyes vulnerable to phototoxicity. Adverse effects associated with the use of light therapy are listed in Table 4. If side effects occur, they typically respond to a “dose” reduction (e.g., decreased duration of sessions, increased distance from the light source or periodic breaks during sessions).
Adverse Effects Associated with Light Therapy
Insomnia (if light therapy is used too late in the day)
Possible retinal damage (although there is no
evidence to date)
Information from reference 22.
Predictors of a positive response to light therapy include disorders characterized by a history of hypersomnia, a preponderance of atypical vegetative symptoms and an increased intake of sweet foods in the afternoon, as well as a history of reactivity to ambient light.[23,24]
Table 5 provides patient resource information, including associations that provide support to persons with SAD and sources for light fixtures.
Resources for Patient with Seasonal Affective Disorders
Places where light fixtures may be purchased:
Apollo Light Systems
352 West 1060 South
Orem, Utah 84058
Hughes Lighting Technologies
34 Yacht Club Dr.
Lake Hopatcong, NJ 07849
Northern Light Technologies
8971 Henri Bourassa West
Montreal, Canada H45 1P7
The SunBox Company
19217 Orbit Dr.
Gaithersburg, MD 20879
Sources of information:
National Organization for Seasonal Affective
P.O. Box 40190
Washington, DC 20016
(Correspondence handled by mail only)
National Depressive and Manic Depressive
730 N. Franklin, Suite 501
Chicago, IL 60610
Telephone: 800-82-NDMDA (800-826-3632)
Society for Light Treatment and Biological Rhythms
10200 W. 44th Ave., # 304
Wheat Ridge, CO 80033-2840
National Institute of Mental Health (NIMH)
National Mental Health Association (NMHA)
1021 Prince St.
Alexandria, VA 22314-2971
NOTE: On average, the price of a light fixture may range between $200 and $500, depending on the features of the unit Some insurance companies may reimburse all or a portion of the cost of a light therapy device if proper diagnosis has been made and treatment has been prescribed by a qualified health professional. Some companies offer a rental program for a “trying out” period.
Although data are limited for the pharmacotherapeutic treatment of SADs specifically, the many studies demonstrating the efficacy of pharmacotherapy in mood disorders, none of which specifically excluded seasonal variations, have supported the use of conventional, first-line antidepressant pharmacotherapy for SADs.
Specific studies of SAD have investigated both antidepressant and nonantidepressant drugs. Few of these studies, however, were placebo-controlled. In controlled trials, fluoxetine, propranolol, and d-fenfluramine have been found effective.[12,25-27] Open trials have also shown favorable results with moclobemide, tranylcypromine and bupropion. Table 6 lists factors suggesting the use of medications in patients with SADs.
Indications For Pharmacotherapy
in Patients with Seasonal Affective Disorders
Prior positive response to antidepressants or mood stabilizers
High suicide risk(*)
Marked impairment in occupational functioning or in usual social
activities or relationships with others; significant functional
History of recurrent depression in the moderate-to-severe range
Severe subtypes of depression (e.g., psychotic, melancholic,
Failure to respond to light therapy or psychotherapy
(*) –Need for hospitalization should be assessed in such cases. Also, the patient’s supply of medications, especially tricyclic antidepressants, should be limited to prevent overdose.
Since SADs may occur concurrently with bipolar or unipolar disorders, the type of disorder should guide medication selection. As with light therapy, physicians should remain sensitive to the risk of precipitating a manic episode in patients with bipolar disorder when using antidepressants.
To our knowledge, no controlled studies have investigated the efficacy of electroconvulsive therapy or psychotherapy for SAD specifically. However, very strong evidence supports the efficacy of electroconvulsive therapy, two forms of psychotherapy (interpersonal psychotherapy and cognitive therapy), and combined psychotherapy and somatic therapy in the treatment of depression.
Accordingly, indications for the use of electroconvulsive therapy in patients with SAD are the same as those in patients with nonseasonal depression and include nonresponse to alternative treatments, high suicide risk, psychotic depression and previous positive response to electroconvulsive therapy.
At this time, interpersonal therapy and cognitive therapy are not contraindicated in patients with SAD. These types of psychotherapy should be considered in patients whose depressive episodes are unipolar, nonpsychotic, nonsevere and not chronic, and in those who do not respond to, who refuse or who cannot participate in phototherapy or pharmacotherapy. Patients with SAD may have personal and interpersonal issues like those occurring in patients with nonseasonal depression and may benefit from the adjunctive use of psychotherapy.
The question of whether light therapy can be combined effectively with pharmacotherapy also awaits controlled study. Although several advantages can be hypothesized (e.g., their concurrent use may ease side effects of medication by allowing lower dosages), current guidelines discourage the simultaneous use of light therapy and medication before either one has been proved insufficient.
Referral and Consultation
Family practice physicians treating patients with SAD may find specialty referral or consultation useful under some circumstances. AHCPR guidelines include circumstances in which referral or consultation is recommended. The guidelines are suggested for use in all types of depression and are not specific to SADs. Since response to light therapy is usually apparent within the first two weeks of therapy (usually within the first few days) and since safety and efficacy have not been fully established beyond two weeks, the AHCPR recommends consultation with a specialist to determine specific risks and benefits for individual patients.
REFERENCES[1.] Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 1994;51:8-19.[2.] American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, D.C.: American Psychiatric Association, 1994:317-91.[3.] Wehr TA, Giesen HA, Schulz PM, Anderson JL, Joseph-Vanderpool JR, Kelly K, et al. Contrasts between symptoms of summer depression and winter depression. J Affect Disord 1991;23:173-83[4.] Oren DA, Rosenthal NE. Seasonal affective disorders. In: Paykel ES, ed. Handbook of affective disorders. 2d ed. London: Churchill Livingstone, 1992:551-67.[5.] Kasper S, Wehr TA, Bartko JJ, Gaist PA, Rosenthal NE. Epidemiological findings of seasonal changes in mood and behavior. Arch Gen Psychiatry 1989; 46:823-33.[6.] Swedo SE, Pleeter JD, Richter DM, Hoffman CL, Allen AJ, Hamburger SD, et al. Rates of seasonal affective disorder in children and adolescents. Am J Psychiatry 1995;152:1016-9.[7.] Beckham EE, Leber WR, Youll LK. The diagnostic classification of depression. In: Beckham EE, Leber WR, eds. Handbook of depression. 2d ed. New York: Guilford, 1995:36-60.[8.] Bauer MS, Dunner DL. Validity of seasonal pattern as a modifier for recurrent mood disorders for DSM-IV. Compr Psychiatry 1993;34:159-70.[9.] van Praag HM. “Make-believes” in psychiatry, or, the perils of progress. New York: Brunner/Mazel, 1993:167-214.[10.] Dilsaver SC, Del Medico VJ, Quadri A, Jaeckle S. Pharmacological responsiveness of winter depression. Psychopharmacol Bull 1990;26:303-9.[11.] Wehr TA, Rosenthal NE. Seasonality and affective illness. Am J Psychiatry 1989;146:829-39.[12.] Tam EM, Lam RW, Levitt AJ. Treatment of seasonal affective disorder: a review. Can J Psychiatry 1995; 40:457-66.[13.] Stewart JW, Quitkin FM, Terman M, Terman JS. Is seasonal affective disorder a variant of atypical depression? Differential response to light therapy. Psychiatry Res 1990;33:121-8.[14.] Agency for Health Care Policy and Research Clinical Practice Guidelines. Depression in primary care. Rockville, Md.: U.S. Department of Health and Human Services, 1993.[15.] Rosenthal NE. Light therapy: theory and practice. Primary Psychiatry 1994;Sept-Oct:31-3.[16.] Sack RL, Lewy AJ, White DM, Singer CM, Fireman MJ, Vandiver R. Morning vs evening light treatment for winter depression. Evidence that the therapeutic effects of light are mediated by circadian phase shifts. Arch Gen Psychiatry 1990;47:343-51.[17.] Wirz-Justice A, Graw P, Krauchi K, Gisin B, Jochum A, Arendt J, et al. Light therapy in seasonal affective disorder is independent of time of day or circadian phase. Arch Gen Psychiatry 1993;50:929-37.[18.] Bauer MS, Kurtz J, et al. Mood and behavioral effects of four-week light treatment in winter depressives and controls. Presented at the third annual meeting of the Society for Light Treatment and Biological Rhythms, Toronto, Ontario, Canada, June 1991.[19.] Rosenthal NE, Moul DE, Hellekson CJ, Oren DA, Frank A, Brainard GC, et al. A multicenter study of the light visor for seasonal affective disorder: no difference in efficacy found between two different intensities. Neuropsychopharmacology 1993;8: 151-60.[20.] Terman JS, Terman M, Schlager D, Rafferty B, Rosofsky M, Link MJ, et al. Efficacy of brief, intense light exposure for treatment of winter depression. Psychopharmacol Bull 1990;26:3-11.[21.] Teicher MH, Glod CA, Oren DA, Schwartz PJ, Luetke C, Brown C, et al. The phototherapy light visor: more to it than meets the eye. Am J Psychiatry 1995;152:1197-202.[22.] Levitt AJ, Joffe RT, Moul DE, Lam RW, Teicher MH, Lebegue B, et al. Side effects of light therapy in seasonal affective disorder. Am J Psychiatry 1993; 150:650-2.[23.] Krauchi K, Wirz-Justice A, Graw R High intake of sweets late in the day predicts a rapid and persistent response to light therapy in winter depression. Psychiatry Res 1993;46:107-17.[24.] Oren DA, Jacobsen FM, Wehr TA, Cameron CL, Rosenthal NE. Predictors of response to phototherapy in seasonal affective disorder. Compr Psychiatry 1992;33:111-4.[25.] Partonen T, Lonnqvist J. Moclobemide and fluoxetine in treatment of seasonal affective disorder. J Affect Disord 1996;25:41:93-9.[26.] Schlager DS. Early-morning administration of short-acting beta blockers for treatment of winter depression. Am J Psychiatry 1994;151:1383-5.[27.] O’Rourke D, Wurtman JJ, Wurtman RJ, Chebli R, Gleason R. Treatment of seasonal depression with d-fenfluramine. J Clin Psychiatry 1989;50:343-7.[28.] Dilsaver SC, Jaeckle RS. Winter depression responds to an open trial of tranylcypromine. J Clin Psychiatry 1990;51:326-9.[29.] Dilsaver SC, Qamar AB, Del Medico VJ. The efficacy of bupropion in winter depression: results of an open trial. J Clin Psychiatry 1992;53:252-5.[30.] American Psychiatric Association. The practice of electroconvulsive therapy: recommendations for treatment, training and privileging. A task force report of the American Psychiatric Association. Washington, D.C.: American Psychiatric Association, 1990.[31.] Markowitz JC, Weissman MM. Interpersonal psychotherapy. In: Beckham EE, Leber WR, eds. Handbook of depression. 2d ed. New York: Guilford, 1995:376-90.[32.] Hollon SD, Shelton RC, Davis DD. Cognitive therapy for depression: conceptual issues and clinical efficacy. J Consult Clin Psychol 1993;61:270-5.[33.] Jarrett RB. Comparing and combining short-term psychotherapy and pharmacotherapy for depression. In: Beckham EE, Leber WR, eds. Handbook of depression. 2d ed. New York: Guilford, 1995: 435-64.
S. ATEZAZ SAEED, M.D., is acting chairman of the Department of Psychiatry and Behavioral Medicine and director of education in psychiatry at the University of Illinois College of Medicine at Peoria. He is also co-director of the Anxiety and Mood Disorders Clinic of the University. Dr. Saeed is a graduate of Dow Medical College, Karachi Pakistan, and completed a residency in psychiatry at the Illinois State Psychiatric Institute, Chicago.
TIMOTHY J. BRUCE, PH.D., is assistant professor of psychology and director of undergraduate medical education at the University of Illinois College of Medicine at Peoria He also is co-director of the Anxiety and Mood Disorders Clinic of the university. Dr. Bruce is a graduate of the State University of New York at Albany and completed a residency in clinical psychology at Wilford Hall USAF Medical Center, San Antonio, Tex.
Address correspondence to S. Atezaz Saeed, M.D., Department of Psychiatry and Behavioral Medicine, University of Illinois College of Medicine at Peoria, 7725 N. Knoxville Ave., Lower Level, Peoria, IL 61614. Reprints are not available from the authors.
COPYRIGHT 1998 American Academy of Family Physicians
COPYRIGHT 2000 Gale Group